Lexicon Pharmaceuticals (LXRX) Research Hub

Lexicon Pharmaceuticals (LXRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2 USD (-6.98%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -31.51, market cap 0.98B. This hub links to the full technical, earnings and options research available for LXRX.

Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ

SectorHealthcare (Biotechnology)
ExchangeNASDAQ, US
Last close2 USD (-6.98%)
52-week range1.92 USD – 2.68 USD
Trend regimeRange
14-day RSI21.7 (Oversold)
Trailing P/E-31.51
Market cap0.98B
Dividend yield0.00%

Available research for LXRX

Earnings

LXRX earnings: real EPS beat/miss history, analyst consensus Hold, P/E -31.51. Updated 2026-07-23.

Options: Covered Call

Covered Call on LXRX: how it works, illustrative setup around the real 2 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Iron Condor

Iron Condor on LXRX: how it works, illustrative setup around the real 2 USD price, max profit/loss, breakeven and when to use it. Educational.

Options: Protective Put

Protective Put on LXRX: how it works, illustrative setup around the real 2 USD price, max profit/loss, breakeven and when to use it. Educational.

Technical

LXRX technical analysis: range, last 2 USD, RSI 21.7, 52w range 1.92 USD–2.68 USD, real support/resistance. Updated 2026-09-11.

Frequently asked questions

What sector is LXRX in?

Lexicon Pharmaceuticals (LXRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.

Is LXRX in an uptrend or downtrend?

As of 2026-09-11, LXRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.

What is LXRX's trailing P/E ratio?

LXRX's trailing P/E is -31.51, with a market cap of 0.98B. See the earnings research page for full valuation detail.